CAS: 360-68-9; (3S,5R,8R,9S,10S,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-Methylheptan-2-yl)Hexadecahydro-1H-Cyclopenta[a]Phenanthren-3-Ol

上下游产品

胆甾烷醇 Epicoprostanol 516-92-7
5α-Cholestan-3β-Yl Acetate 1255-88-5
5α-Cholestan-3β-Yl Acetate 4947-63-1

📜4-胆甾烯-3-酮置于intestine Bacteria体系中,化学反应生成 粪甾烷-3-醇
参考文献:动物体内粪甾醇和胆汁酸的前体
标题:动物体内粪甾醇和胆汁酸的前体
摘要:胆固醇在通过身体时转化为粪前列醇涉及 C5:C6 双键的还原,以及从异胆酸环系统到胆酸环系统的转变.虽然已经确定肠道菌群参与还原过程,但立体化学变化的机制尚不清楚.研究 Cholestene-3:4-Diol 的特性提供了一条线索,Cholestene-3:4-Diol 是一种主要氧化产物,在胆固醇轻度氧化的各种条件下形成,也是称为"氧胆固醇"1 的树脂产物的成分.作为一种α-乙二醇,这种物质很容易通过失去水分而重新排列成相应的酮,即胆甾酮.由于胆甾酮(= 粪前列酮)在还原时产生粪前列酮,反过来又可还原为粪前列醇(= 粪前列醇)和表粪前列醇 2,3,我们形成了工作假设,即反应性初级氧化产物胆甾烯二醇可能在胆固醇代谢中发挥作用,导致胆甾酮的形成一种中间产品.在这种假设下,胆甾酮和粪前列酮,而不是胆固醇本身,是粪甾醇的直接前体,粪甾醇是在肠道中通过细菌还原形成的.此外,还解释了石胆酸(和其他胆汁酸)4
DOI:10.1038/136474A0

专利信息

专利号:US-2024294462-A1
优先权日:2023-02-15
标题:Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate
发明人：SAADATI FARIBA; TRAN HUY; CIUFOLINI MARCO; ATMURI N D PRASAD
权利人:NANOVATION THERAPEUTICS INC
摘要:Provided herein is a method for the preparation of ionizable, cationic amino lipids using a doubly alkylated nucleophilic intermediate to produce a ketone. The ketone, or a corresponding alcohol, is subjected to one or more synthesis steps to add an ionizable moiety thereto. The method can be advantageously employed for the synthesis of unsymmetrical analogues of the above lipids that would be considerably more difficult to make by alternative strategies. The method can also be used to prepare symmetrical ionizable, cationic amino lipids with fewer steps and/or with the use of fewer hazardous chemicals than known synthesis methods.

专利号:US-2025049714-A1
优先权日:2021-12-09
标题 :Synthesis of ester, carbonate, and carbamate-derived novel biodegradable ionizable lipids from methyl ricinoleate or methyl 12-hydroxystearate and its applications
发明人：ANDERSON DANIEL GRIFFITH; RHYM LUKE HYUNSIK; LI BOWEN; GORDON AKIVA; RAJITH SINGH MANAN; WITTEN JACOB
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of polynucleotides, such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, liver disease, spleen disease, lung disease, painful condition, psychiatric disorder, musculoskeletal disease, a metabolic disorder, inflammatory disease, or autoimmune disease).

专利号:US-2008300418-A1
优先权日:2004-11-08
标 题:Synthesis of Cardiolipin Analogues and Uses Thereof
发明人：AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
摘要:The invention provides novel synthetic methodologies for preparing cardiolipin, migrated caridiolipin (1,2-positional isomer of cardiolipin) and their analogues having varying fatty acids and/or alkyl chains with varying length and degrees of saturation/unsaturation. The method comprises (a) reacting an optically pure 1,2-O-dialkyl-sn-glycerol or 1,2-O-dialkyl-sn-glycerol with one or more phosphoramidite reagent(s), wherein a phosphite triester is produced; (b) coupling the product of (a) with glycerol, wherein a protected cardiolipin is produced; and (c) deprotecting the protected cardiolipin, such that cardiolipin is prepared. The cardiolipins and analogues thereof, prepared by the present methods, can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or can be used in diagnostic and/or analytical assays.

专利号:US-2024226302-A1
优先权日:2022-12-27
标题:Biodegradable lipids and formulations for intramuscular, in vitro, and ex vivo transfection of mrna
发明人：ANDERSON DANIEL GRIFFITH; RUDRA AMAB; GUPTA AKASH; REED KAELAN
权利人:MASSACHUSETTS INST TECHNOLOGY; CHILDRENS MEDICAL CENTER
摘要:Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I) and (II).

专利号:US-2025205158-A1
优先权日:2023-12-26
标 题 :Biodegradable lipids and formulations for delivery of mrna
发明人：ANDERSON DANIEL GRIFFITH; RUDRA ARNAB; GUPTA AKASH; REED KAELAN
权利人:MASSACHUSETTS INST TECHNOLOGY; CHILDRENS MEDICAL CENTER
摘要:Provided herein are compounds, such as compounds of Formulae (I), (I′), (XI), (XII), and (XIII), and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I′), (XI), (XII), (XIII), and (VIII).

专利号:US-2004121992-A1
优先权日:2002-09-10
标 题 :Therapeutic methods of reducing cholesterol accumulation
发明人：JAVITT NORMAN B
摘要:Methods of reducing the cholesterol accumulation in a subject, including methods of reducing cholesterol synthesis and methods of increasing cholesterol degradation. Cholesterol synthesis is inhibited by administering a compound capable of increasing 27-hydroxy-7-dehydrocholesterol and/or 27-hydroxy-8-dehydrocholesterol levels, wherein an increase in 27-hydroxy-7-dehydrocholesterol and/or 27-hydroxy-8-dehydrocholesterol levels results in an inhibition of cholesterol synthesis. Cholesterol degradation is increased by increasing the level of 7α-hydroxylase in extrahepatic tissue and cells.